Emerging evidence suggests GLP-1 receptor agonists may reduce nicotine cravings through brain reward pathways while simultaneously preventing post-cessation weight gain — but rigorous clinical trials are still needed.
Dual-target potentialGLP-1 agonists may address nicotine cravings through brain reward circuits while simultaneously preventing the weight gain that drives many smokers to relapse
What the researchers found
The review synthesizes preclinical and limited clinical evidence showing that GLP-1 receptor agonists may address nicotine dependence through two mechanisms:
1. **Reduced nicotine cravings**: GLP-1 RAs modulate central reward pathways (mesolimbic dopamine system) that underlie nicotine's addictive properties, potentially reducing cravings and nicotine intake.
2. **Weight gain prevention**: The well-established appetite-suppressing and weight-loss effects of GLP-1 RAs could counteract the metabolic changes that follow nicotine withdrawal (increased caloric intake, reduced energy expenditure).
This dual mechanism could improve quit success rates while eliminating one of the primary psychological barriers to smoking cessation.
Why it matters
Smoking kills over 8 million people annually, and weight gain after quitting is both a health risk and a major deterrent to quitting. If GLP-1 agonists — already prescribed to millions for weight loss — can simultaneously address nicotine addiction, it could revolutionize smoking cessation and prevent relapse in a population that has been underserved by existing quit-smoking medications.
How the study worked
This is a narrative review synthesizing evidence from preclinical animal studies, limited clinical trials, and pharmacological literature on GLP-1 receptor agonists' effects on nicotine dependence and post-cessation weight management.
What this study cannot tell us
The human evidence base is very limited: small sample sizes, short follow-up periods, and reliance on preliminary or observational data. No large randomized controlled trials specifically testing GLP-1 RAs for smoking cessation have been completed. Potential side effects (nausea, pancreatitis risk) and the cost of GLP-1 drugs could limit real-world applicability. The narrative review format does not systematically assess study quality or risk of bias.
How to read the evidence
This is a narrative review based primarily on preclinical data and limited clinical observations. While the biological rationale is compelling, the lack of large randomized controlled trials means the evidence for GLP-1 agonists as smoking cessation aids remains preliminary.
When this study was published
Published in 2026, this review captures the current wave of interest in GLP-1 agonists' effects on addictive behaviors — a topic receiving enormous public and scientific attention.
The bigger picture
This review reflects a broader trend of discovering that GLP-1 agonists affect far more than blood sugar and weight. Reports of reduced cravings for alcohol, nicotine, and other substances in patients taking these drugs have generated enormous public interest. If confirmed in rigorous trials, GLP-1 agonists could become the first medication class to simultaneously treat obesity, diabetes, cardiovascular disease, and addiction — a remarkably broad therapeutic profile.
Questions still open
- Will ongoing randomized controlled trials confirm that GLP-1 agonists meaningfully improve smoking quit rates compared to existing medications like varenicline?
- At what dose and duration are GLP-1 agonists most effective for nicotine craving reduction — is it the same as for weight loss?
- Could GLP-1 agonists be combined with existing quit-smoking therapies (nicotine replacement, bupropion) for additive effects?
Common questions
Can my doctor prescribe Ozempic or Wegovy to help me quit smoking?
Why would a diabetes drug help with nicotine addiction?
Read the original research
GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.
Annals of medicine and surgery (2012), 88(3), 2373-2382
Citation
Ahmed, Ghazi Uddin; Zehra, Eiman; Rasheed, Sana; Akhtar, Syed Owais; Raza, Ahmed Asad; Mujaddadi, Khunsha; Samadi, Abedin. (2026). GLP-1 receptor agonists for smoking cessation: a narrative review of weight management potential.. Annals of medicine and surgery (2012), 88(3), 2373-2382. https://doi.org/10.1097/MS9.0000000000004725